Literature DB >> 16969838

Reliable surrogate outcome measures in multicenter clinical trials of Duchenne muscular dystrophy.

Jill E Mayhew1, Julaine M Florence, Thomas P Mayhew, Erik K Henricson, Robert T Leshner, Robert J McCarter, Diana M Escolar.   

Abstract

We studied the reliability of a series of endpoints in an evaluation of subjects with Duchenne muscular dystrophy (DMD). The endpoints included quantitative muscle tests (QMTs), timed function tests, forced vital capacity (FVC), and manual muscle tests (MMT). Thirty-one ambulatory subjects with DMD (mean age 8.9 years; range 5-16 years) were evaluated at eight sites by 15 newly trained evaluators as a test of interrater reliability of outcome measures. Both total QMT score [intraclass correlation coefficient (ICC) 0.96] and individual QMT assessments (ICC 0.85-0.96) were highly reliable. Forced vital capacity and all timed function tests were also highly reliable (ICC 0.97-0.99). MMT was the least reliable assessment method (ICC 0.61). These data suggest that primary surrogate outcome measures in large multicenter clinical trials in DMD should use QMT, FVC, or time function tests to obtain maximum power and greatest sensitivity.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 16969838     DOI: 10.1002/mus.20654

Source DB:  PubMed          Journal:  Muscle Nerve        ISSN: 0148-639X            Impact factor:   3.217


  44 in total

1.  Pentoxifylline as a rescue treatment for DMD: a randomized double-blind clinical trial.

Authors:  D M Escolar; A Zimmerman; T Bertorini; P R Clemens; A M Connolly; L Mesa; K Gorni; A Kornberg; H Kolski; N Kuntz; Y Nevo; C Tesi-Rocha; K Nagaraju; S Rayavarapu; L P Hache; J E Mayhew; J Florence; F Hu; A Arrieta; E Henricson; R T Leshner; J K Mah
Journal:  Neurology       Date:  2012-03-07       Impact factor: 9.910

2.  Muscle fat-fraction and mapping in Duchenne muscular dystrophy: evaluation of disease distribution and correlation with clinical assessments. Preliminary experience.

Authors:  Michele Gaeta; Sonia Messina; Achille Mileto; Gian Luca Vita; Giorgio Ascenti; Sergio Vinci; Antonio Bottari; Giuseppe Vita; Nicola Settineri; Daniele Bruschetta; Sergio Racchiusa; Fabio Minutoli
Journal:  Skeletal Radiol       Date:  2011-11-10       Impact factor: 2.199

3.  Randomized, blinded trial of weekend vs daily prednisone in Duchenne muscular dystrophy.

Authors:  D M Escolar; L P Hache; P R Clemens; A Cnaan; C M McDonald; V Viswanathan; A J Kornberg; T E Bertorini; Y Nevo; T Lotze; A Pestronk; M M Ryan; E Monasterio; J W Day; A Zimmerman; A Arrieta; E Henricson; J Mayhew; J Florence; F Hu; A M Connolly
Journal:  Neurology       Date:  2011-07-13       Impact factor: 9.910

4.  Electrical impedance myography for assessment of Duchenne muscular dystrophy.

Authors:  Seward B Rutkove; Kush Kapur; Craig M Zaidman; Jim S Wu; Amy Pasternak; Lavanya Madabusi; Sung Yim; Adam Pacheck; Heather Szelag; Tim Harrington; Basil T Darras
Journal:  Ann Neurol       Date:  2017-05-04       Impact factor: 10.422

5.  Age-related differences in lower-limb muscle cross-sectional area and torque production in boys with Duchenne muscular dystrophy.

Authors:  Sunita Mathur; Donovan J Lott; Claudia Senesac; Sean A Germain; Ravneet S Vohra; H Lee Sweeney; Glenn A Walter; Krista Vandenborne
Journal:  Arch Phys Med Rehabil       Date:  2010-07       Impact factor: 3.966

6.  Clinical heterogeneity of duchenne muscular dystrophy (DMD): definition of sub-phenotypes and predictive criteria by long-term follow-up.

Authors:  Isabelle Desguerre; Christo Christov; Michele Mayer; Reinhard Zeller; Henri-Marc Becane; Sylvie Bastuji-Garin; France Leturcq; Catherine Chiron; Jamel Chelly; Romain K Gherardi
Journal:  PLoS One       Date:  2009-02-05       Impact factor: 3.240

7.  The use of muscle strength assessed with handheld dynamometers as a non-invasive biological marker in myotonic dystrophy type 1 patients: a multicenter study.

Authors:  Luc J Hébert; Jean-François Remec; Joanne Saulnier; Christophe Vial; Jack Puymirat
Journal:  BMC Musculoskelet Disord       Date:  2010-04-18       Impact factor: 2.362

8.  Physical training in boys with Duchenne Muscular Dystrophy: the protocol of the No Use is Disuse study.

Authors:  Merel Jansen; Imelda Jm de Groot; Nens van Alfen; Alexander Ch Geurts
Journal:  BMC Pediatr       Date:  2010-08-06       Impact factor: 2.125

9.  Lack of functional benefit with glutamine versus placebo in Duchenne muscular dystrophy: a randomized crossover trial.

Authors:  Elise Mok; Guy Letellier; Jean-Marie Cuisset; André Denjean; Frédéric Gottrand; Corinne Alberti; Régis Hankard
Journal:  PLoS One       Date:  2009-05-06       Impact factor: 3.240

10.  The cooperative international neuromuscular research group Duchenne natural history study--a longitudinal investigation in the era of glucocorticoid therapy: design of protocol and the methods used.

Authors:  Craig M McDonald; Erik K Henricson; R Ted Abresch; Jay J Han; Diana M Escolar; Julaine M Florence; Tina Duong; Adrienne Arrieta; Paula R Clemens; Eric P Hoffman; Avital Cnaan
Journal:  Muscle Nerve       Date:  2013-05-16       Impact factor: 3.217

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.